Dyne Therapeutics (DYN) received orphan drug designation from the European Commission for its candidate drug DYNE-251 to treat Duchenne muscular dystrophy.
The drug is being assessed in phase 1/2 of a global trial in people with the disease who are amenable to exon 51 skipping, the company said Thursday in a statement.
"With full enrollment of the registrational expansion cohort in the DELIVER trial complete, we look forward to sharing data from this cohort in late 2025 and the potential to move forward with our first regulatory submissions in early 2026," Dyne Chief Medical Officer Doug Kerr said.
Dyne shares rose 3.1% in recent Thursday trading.
Price: 11.11, Change: +0.33, Percent Change: +3.06
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。